Company Overview - Disc Medicine has been publicly listed for approximately three years and has experienced a productive journey during this period [3] - The company is on the verge of approval for its lead program and has a robust pipeline of additional programs progressing well [3] Clinical Programs - The presentation will cover three investigational agents: bitopertin, DISC-0974, and DISC-3405, which are not yet approved as therapies anywhere in the world [4] - The company aims to provide updates on the progress towards approval for its lead program and discuss launch strategies [5]